<DOC>
	<DOCNO>NCT02950805</DOCNO>
	<brief_summary>This study assess effect inhale AZD5634 Mucociliary clearance ( MCC ) patient Cystic fibrosis ( CF ) single-dose administration .</brief_summary>
	<brief_title>A Study Assess Effect AZD5634 Mucociliary Clearance , Safety , Tolerability Pharmacokinetic Parameters Patients With Cystic Fibrosis</brief_title>
	<detailed_description>The primary pharmacodynamic endpoint average whole lung particle clearance 0 60 minute administration aerosolize radiolabelled particle ( colloid ) Visits 2 3 ( % MCC 0-60 , whole ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<criteria>1 . Provision sign date write informed consent prior studyspecific procedure . 2 . Male female patient age 1860 year old inclusive . 3 . Diagnosed CF Screening evidence medical record one follow criterion : 1. sweat chloride ≥ 60 mmol/L 2. presence 2 mutation Cystic Fibrosis Transmembrane Conductance Regulator ( CFTR ) gene . 4 . Chronic sinopulmonary disease pancreatic insufficiency . 5 . FEV1measurement Screening ≥ 40 % predict normal value age , height , gender , race . 6 . Stable CF regimen least 2 month Screening . 7 . Body mass index ( BMI ) 1530 kg/m2 inclusive . 8 . Female patient pregnant plan become pregnant study , lactate , nonchildbearing potential . Females childbearing potential must provide negative serum pregnancy test date last menstruation consistent nonpregnancy , negative urine pregnancy test visit , must use least one highly effective method contraception . 9 . Ability patient correctly perform inhalation procedure train Screening Visit . 1 . Had pulmonary exacerbation require change antibiotic and/or hospitalization within 28 day first dose Investigational product . 2 . History lung transplant transplantation . 3 . Currently treat ivacaftor monotherapy Screening receive ivacaftor monotherapy within 30 day Screening . 4 . History severe allergy/hypersensitivity ongoing clinically significant allergy/hypersensitivity , judge Investigator , drug similar class AZD5634 . 5 . History presence hepatic cirrhosis . 6 . Creatinine clearance &lt; 60 mL/min/m2 use CockroftGault Equation . 7 . Liver function test result &gt; 2x upper limit normal ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , gammaglutamyl transpeptidase [ GGT ] , bilirubin ) 8 . History clinically significant disease disorder , opinion Investigator , may either put patient risk participation study , influence result patient 's ability participate study . 9 . Received treatment follow medication within 3 week Screening : strong moderate Cytochrome P450 ( CYP ) 3A inhibitor , classify Food Drug Administration ( FDA ) . 10 . Likely require treatment study drug permit study protocol . 11 . Any clinically significant abnormality clinical chemistry , hematology , urinalysis result . 12 . Serum potassium level outside normal range ( 3.55.1 mmol/L ) . 13 . Serum sodium level &lt; 135 mmol/L . 14 . Abnormal vital sign , 5 minute rest , Screening Visit 2 ( seat supine ; position consistent give patient visit ) , define follow : Systolic blood pressure ( B.P ) &lt; 90 ≥ 150 mmHg Diastolic B.P &lt; 45 ≥ 90 mmHg Pulse rate &lt; 45 &gt; 110 beats/minute 15 . Any clinically significant abnormality rhythm , conduction , morphology rest ECG clinically significant abnormality 12lead ECG , consider Investigator , may interfere interpretation correct ECG interval measure onset QRS complex offset T wave ( QTc ) interval change . 16 . QTc prolongation define QT interval correct heart rate use Fridericia 's formula ( QTcF ) &gt; 450 ms. 17 . ECG interval measure onset P wave onset QRS complex ( PR/PQ ) interval prolongation ( &gt; 240 m ) , intermittent second third degree atrioventricular ( AV ) block , AV dissociation . 18 . Persistent intermittent complete bundle branch block ( BBB ) ECG interval measure onset QRS complex J point ( QRS ) &gt; 120 ms evidence preexcitation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>AZD5634</keyword>
	<keyword>Mucociliary Clearance</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Cross-Over Study</keyword>
</DOC>